UNCY
Price:
$0.5001
Market Cap:
$47.19M
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.[Read more]
Industry
Biotechnology
IPO Date
2021-07-12
Stock Exchange
NASDAQ
Ticker
UNCY
According to Unicycive Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 52.23M. This represents a change of 92.43% compared to the average of 27.14M of the last 4 quarters.
The mean historical Enterprise Value of Unicycive Therapeutics, Inc. over the last ten years is 44.59M. The current 52.23M Enterprise Value has changed 11.61% with respect to the historical average. Over the past ten years (40 quarters), UNCY's Enterprise Value was at its highest in in the December 2020 quarter at 75.00M. The Enterprise Value was at its lowest in in the June 2019 quarter at 0.
Average
44.59M
Median
45.65M
Minimum
7.83M
Maximum
78.75M
Discovering the peaks and valleys of Unicycive Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 58.38%
Maximum Annual Enterprise Value = 78.75M
Minimum Annual Increase = -81.43%
Minimum Annual Enterprise Value = 7.83M
Year | Enterprise Value | Change |
---|---|---|
2023 | 12.40M | 58.38% |
2022 | 7.83M | -46.44% |
2021 | 14.62M | -81.43% |
2020 | 78.75M | 2.70% |
2019 | 76.68M | -0.75% |
The current Enterprise Value of Unicycive Therapeutics, Inc. (UNCY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
11.62M
5-year avg
38.06M
10-year avg
44.59M
Unicycive Therapeutics, Inc.’s Enterprise Value is greater than TransCode Therapeutics, Inc. (5.16M), less than Ambrx Biopharma Inc. (1.56B), greater than Cardio Diagnostics Holdings, Inc. (6.29M), greater than Hillstream BioPharma, Inc. (1.48M), less than SeqLL Inc. (264.18M),
Company | Enterprise Value | Market cap |
---|---|---|
5.16M | $8.29M | |
1.56B | $1.77B | |
6.29M | $6.73M | |
1.48M | $4.17M | |
264.18M | $185.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Unicycive Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Unicycive Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Unicycive Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
What is the 3-year average Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
What is the 5-year average Enterprise Value for Unicycive Therapeutics, Inc. (UNCY)?
How does the current Enterprise Value for Unicycive Therapeutics, Inc. (UNCY) compare to its historical average?